Composition capable of delaying muscle aging and application thereof

Abstract

The invention belongs to the field of pharmaceutical compositions, and relates to a composition for delaying muscle aging and application thereof. The composition comprises curcumin and milk-derived protein, and can help to delay the problems of muscle atrophy, muscle movement ability decline and the like caused by muscle aging. The composition has both functionality and nutrition, and shows a wide application prospect in the aspects of improving muscle functions and athletic ability.

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical compositions, relates to an anti-muscle aging composition, and particularly relates to a composition capable of delaying muscle aging and its application. Background Art

[0002] Skeletal muscle accounts for 40-50% of the total body weight of the human body. It is the most important locomotor organ of the body and also the main site of energy metabolism. In aging individuals, insulin sensitivity decreases. As the main organ of glucose metabolism, skeletal muscle has a significantly reduced ability to utilize glucose, resulting in insufficient energy supply, atrophy, and reduced motor ability. Skeletal muscle atrophy caused by muscle aging not only seriously impairs the mobility of the elderly, but also induces various chronic diseases.

[0003] Research shows that the muscle-building effect of whey protein is significantly better than that of other animal and plant proteins. As the main component of cow's milk, the key protein that exerts the muscle-building effect has not been clarified. Therefore, selecting the main components of whey protein, namely α-lactalbumin, β-lactoglobulin, and lactoferrin, may have a good muscle-building effect.

[0004] However, there is currently a lack of research on the combined effect of milk-derived proteins and other functional components on skeletal muscle aging or atrophy. Summary of the Invention

[0005] Aiming at the deficiencies of the prior art, the present invention uses the food-derived active substance curcumin with anti-inflammatory and antioxidant properties to provide a microenvironment conducive to protein synthesis for muscle fibers, and combines the administration of milk-derived proteins to provide raw materials for protein synthesis, thereby developing a composition that can significantly alleviate muscle atrophy. Specifically, the present invention aims to provide a composition for alleviating muscle atrophy and its application. By compounding curcumin and milk-derived proteins, problems such as muscle atrophy and decreased muscle motor ability caused by delaying muscle aging are solved.

[0006] To achieve the above object, in a first aspect, the present invention provides a composition capable of alleviating muscle atrophy, the composition comprising curcumin and milk-derived protein, and the mass ratio of curcumin to milk-derived protein is 1-3:1-3, such as 1:1, 1:2, 1:3, 2:1, 2:2, 2:3, 3:1, 3:2.

[0007] Further, the milk-derived protein is one or more of lactoferrin, α-lactalbumin, or β-lactoglobulin.

[0008] Further, the mass ratio of curcumin to milk-derived protein is 1-2:1-2.

[0009] Even further, the mass ratio of curcumin to milk-derived protein is 1:1.

[0010] In a second aspect, the present invention provides a product, which comprises the composition described in the first aspect.

[0011] Further, the product is a feed, a health food or a medicine, and the product further comprises excipients acceptable in feeds, health foods or medicines.

[0012] In a third aspect, the present invention provides the use of the composition described in the first aspect in the preparation of a product capable of delaying muscle aging.

[0013] Further, the product is a feed, a health food or a medicine.

[0014] Further, the delaying of muscle aging includes at least one of the following: (1) Alleviating muscle atrophy; (2) Promoting muscle generation; (3) Improving muscle motor ability.

[0015] Even further, the muscle is skeletal muscle.

[0016] Even further, the muscle is the tibialis anterior muscle.

[0017] Even further, the improving of muscle motor ability includes improving muscle strength or improving muscle endurance.

[0018] In a fourth aspect, the present invention provides the use of the composition described in the first aspect in the preparation of a product capable of alleviating weight loss caused by poor muscle condition.

[0019] Further, the product is a feed, a health food or a medicine.

[0020] In a fifth aspect, the present invention provides the use of the composition described in the first aspect in the preparation of a product capable of maintaining blood glucose stability.

[0021] Further, the product is a feed, a health food or a medicine.

[0022] Compared with the prior art, the present invention has the following advantages: The present invention proves that the combined intervention of curcumin and milk-derived protein can help delay problems such as muscle atrophy and decline in muscle motor ability caused by muscle aging, can effectively improve muscle condition and inhibit muscle aging, and these two components have a synergistic effect. This composition takes into account both functionality and nutrition, and shows broad application prospects in improving muscle function and motor ability. Description of the Drawings

[0023] Figure 1 Shows the effect of the curcumin and protein composition on the body weight of mice.

[0024] Figure 2The effects of curcumin and protein compositions on the ratio of muscle mass to body weight in mice. Among them, A shows the ratio of lean muscle mass to body weight, and B shows the ratio of the tibialis anterior muscle to body weight.

[0025] Figure 3 The effects of curcumin and protein compositions on the motor ability of mice. Among them, A shows the effect on grip strength, and B shows the effect on running time.

[0026] Figure 4 The effects of curcumin and protein compositions on the oral glucose tolerance of mice. Among them, A shows the change of blood glucose concentration over time, and B shows the blood glucose concentration at 30 min.

[0027] Figure 5 The effects of curcumin and protein compositions on the content of ATP in mouse muscle cells.

[0028] Different letters indicate significant differences between groups (P < 0.05). Detailed implementation manners

[0029] The following further elaborates on the concept and technical effects of the present invention in combination with specific embodiments to fully understand the purpose, features, and effects of the present invention. The methods are conventional methods unless otherwise specified. The materials can be obtained from public commercial channels unless otherwise specified. The illustrative embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. It should be noted that, without conflict, the embodiments and features in the embodiments of the present invention can be combined with each other.

[0030] The sources of materials used in the experiment are as follows: Curcumin was purchased from MEC, α-lactalbumin and β-lactoglobulin were purchased from Western Dairy, and lactoferrin was purchased from Wallenberg.

[0031] Embodiment The present invention uses subcutaneous injection of D-galactose (D-gal) at a dose of 500 mg / kg BW to construct a sarcopenia model, and curcumin, α-lactalbumin, β-lactoglobulin, and lactoferrin (the monomer concentration is 200 mg / kg BW for each) are administered by gavage. Curcumin and various milk protein compositions (protein concentration is 100 mg / kg BW, and curcumin concentration is 100 mg / kg BW) are used for intervention, and the experimental period is 8 weeks. The specific grouping is as follows: (1) Blank control group (CK): Inject normal saline and administer normal saline by gavage; (2) Model group (Mod): Use subcutaneous injection of D-galactose at a dose of 500 mg / kg BW to construct a sarcopenia model and administer normal saline by gavage; (3) Curcumin group (Cur): A sarcopenia model was established by subcutaneous injection of galactose at a dose of 500 mg / kg BW, and curcumin (200 mg / kg BW) was administered by gavage; (4) α-lactalbumin group (α-ALA): A sarcopenia model was established by subcutaneous injection of galactose at a dose of 500 mg / kg BW, and α-lactalbumin (200 mg / kg BW) was administered by gavage; (5) β-lactoglobulin group (β-LG): A sarcopenia model was established by subcutaneous injection of galactose at a dose of 500 mg / kg BW, and β-lactoglobulin (200 mg / kg BW) was administered by gavage; (6) Lactoferrin group (LF): A sarcopenia model was established by subcutaneous injection of galactose at a dose of 500 mg / kg BW, and lactoferrin (200 mg / kg BW) was administered by gavage; (7) Curcumin + α-lactalbumin combination group (Cur + ALA): A sarcopenia model was established by subcutaneous injection of galactose at a dose of 500 mg / kg BW, and a combination of curcumin and α-lactalbumin (curcumin concentration was 100 mg / kg BW, α-lactalbumin concentration was 100 mg / kg BW) was administered by gavage; (8) Curcumin + β-lactoglobulin combination group (Cur + LG): A sarcopenia model was established by subcutaneous injection of galactose at a dose of 500 mg / kg BW; A combination of curcumin and β-lactoglobulin (curcumin concentration was 100 mg / kg BW, β-lactoglobulin was 100 mg / kg BW) was administered by gavage.

[0032] (9) Curcumin + lactoferrin combination group (Cur + LF): A sarcopenia model was established by subcutaneous injection of galactose at a dose of 500 mg / kg BW, and a combination of curcumin and lactoferrin (curcumin concentration was 100 mg / kg BW, lactoferrin concentration was 100 mg / kg BW) was administered by gavage.

[0033] As Figures 1-3 shown, compared with the control group, the body weight, muscle mass ratio, grip strength and running time of the model group were significantly decreased, indicating that obvious muscle atrophy occurred and muscle function declined, and the mouse sarcopenia model was successfully established.

[0034] Performance Test Example 1 Effects of Different Combinations on Mouse Body Weight As Figure 1As shown, a sarcopenia model was constructed with D-galactose, accompanied by a decrease in the body weight of mice. Compared with the model group, curcumin intervention could significantly increase the body weight gain of mice (P<0.05); compared with the model group, the body weight gain of mice in the intervention groups of α-lactalbumin, β-lactoglobulin and lactoferrin monomers increased slightly, but there was no significant difference ( P <0.05). Compared with the corresponding monomers, the curcumin+α-lactalbumin and curcumin+β-lactoglobulin compositions had no significant effect on increasing the body weight gain of mice; relative to the model group, the curcumin+lactoferrin composition had a significant effect on increasing the body weight gain of mice, and could promote the body weight to recover to a level close to that of normal mice. The promotion of body weight by the curcumin+lactoferrin composition was 1.24 times and 1.29 times that of the curcumin+α-lactalbumin and curcumin+β-lactoglobulin compositions respectively, and the effect was more significant than that of the curcumin or lactoferrin administration group alone, that is, the curcumin+lactoferrin composition had a better effect on increasing the body weight of sarcopenia mice than when curcumin or lactoferrin was applied alone, indicating that curcumin and lactoferrin had a synergistic effect in increasing the body weight of sarcopenia mice.

[0035] Performance test example 2 Effects of different compositions on muscle generation in mice The total lean (muscle) mass of mice and the proportion of the body weight of the tibialis anterior muscle in the lower limbs were measured. It can be seen that Figure 2 compared with the control group, the lean mass and the proportion of the body weight of the tibialis anterior muscle in the model group were significantly decreased (P<0.05); compared with the model group, curcumin, α-lactalbumin, β-lactoglobulin, lactoferrin monomers, and curcumin+albumin and curcumin+globulin compositions all had an effect on increasing the proportion of total lean (muscle) mass and the proportion of the body weight of the tibialis anterior muscle. The promotion of the tibialis anterior muscle in the curcumin+lactoferrin composition group was 1.11 and 1.15 times that of the curcumin+albumin and curcumin+globulin compositions respectively, and the muscle-building effect of the curcumin+lactoferrin composition was better than that of the curcumin administration group alone and the lactoferrin administration group alone (P<0.05), that is, the curcumin+lactoferrin composition had a better effect on promoting muscle generation in mice than when curcumin or lactoferrin was applied alone, indicating that curcumin and lactoferrin had a synergistic effect in promoting muscle generation in mice.

[0036] Performance test example 3 Effects of different compositions on the muscle movement ability (muscle state) of mice The test of the muscle movement ability of mice mainly includes the measurement of the grasping force and running time of mice, where the grasping force represents the strength of the muscle and the running time represents the endurance of the muscle.

[0037] As Figure 3As shown, compared with the control group, the running time and grip strength of the model group were significantly reduced (P<0.05); compared with the model group, the intervention of each monomer substance group could significantly increase the running time and grip strength of mice (P<0.05).

[0038] The curcumin + α-lactalbumin composition could significantly increase the running time and grip strength of mice, and the promoting effect was more significant than that of the curcumin alone administration group and the α-lactalbumin alone administration group. It can be seen that curcumin and α-lactalbumin have a synergistic effect in improving muscle strength.

[0039] The curcumin + β-lactoglobulin composition could significantly increase the running time and grip strength of mice, and the promoting effect was more significant than that of the curcumin alone administration group and the β-lactoglobulin alone administration group. It can be seen that curcumin and β-lactoglobulin have a synergistic effect in improving muscle strength.

[0040] The curcumin + lactoferrin composition could significantly increase the running time of mice (up to 1057 seconds), and the promoting effect was more significant than that of its single administration. The effect of this composition on improving the exercise endurance of mice was 1.24 times that of curcumin / lactoferrin alone (P<0.05), and the effect on improving the exercise time was about 17% higher than that of the other two compositions (P<0.05).

[0041] The curcumin + lactoferrin composition could also significantly improve the grip strength of mice, which was 24% and 13% higher than that of curcumin and lactoferrin respectively, and the promoting effect of this composition on grip strength was more significant than that of its single administration, that is, its effect on improving grip strength was better than that of curcumin alone or lactoferrin alone, indicating that curcumin and lactoferrin have a synergistic effect in improving muscle strength.

[0042] Performance test example 4 Effect of different compositions on oral glucose tolerance in mice Skeletal muscle is the main organ for glucose metabolism, and muscle atrophy can lead to insulin resistance in the body. Therefore, maintaining muscle mass is crucial for the stability of blood glucose in the body. The mice were taken out of the cage and gently placed on the iron grid. The end of the mouse's tail was cut off by 1-2 mm with scissors, and the mouse's tail was gently squeezed to make the blood gather into a drop. The fasting blood glucose was measured with a blood glucose meter, and the measured value was recognized as the blood glucose value at 0 minutes. Then the mice were weighed and recorded. The dose of glucose to be injected for each mouse was calculated according to the amount of 2 g / kg body weight. After oral glucose administration, the blood glucose concentrations of each group of mice were sampled and measured at 30 minutes, 60 minutes, 90 minutes, 120 minutes and 180 minutes. As Figure 4As shown, the blood glucose concentration of mice in each treatment group increased rapidly and reached the highest value at 15 - 30 min. After that, the blood glucose concentration decreased rapidly and dropped to the normal level at about 120 min. At 30 min, the blood glucose concentration of mice in the model group was significantly higher than that in the control group. Each intervention group could reduce the blood glucose level. The curcumin + lactoferrin group had the best reducing effect, which was not only significantly lower than that of the monomer group but also better than the other two intervention substances (P < 0.05). Since the curcumin + lactoferrin group had a better effect on maintaining blood glucose stability than the curcumin monomer group and the lactoferrin monomer group, it can be seen that curcumin and lactoferrin have a synergistic effect in maintaining blood glucose stability.

[0043] Performance Test Example 5 Effect of Different Compositions on Muscle Cell Energy Production Mitochondrial homeostasis is an important factor determining skeletal muscle function. Skeletal muscle is rich in mitochondria due to its special demand for ATP, and it is crucial for muscle cells to maintain normal energy production to maintain their physiological functions.

[0044] Operate according to the instructions of the mitochondrial stress kit (Agilent), and measure the oxygen consumption rate (OCR) of mitochondria with an extracellular flux analyzer. The rate measurement formula is as follows: ATP production = (the last measurement rate before injecting oligomycin) - the minimum rate after injecting oligomycin. As Figure 5 As shown, compared with the cells in the control group, the ATP production of D-gal-induced C2C12 cells decreased by 51%. Compared with the model group, the intervention of each monomer substance group could significantly increase the ATP content in muscle cells (P < 0.05); among them, the curcumin + lactoferrin composition had a more significant promoting effect on the ATP production of muscle cells than when administered alone. After the intervention of this composition on muscle cells, the ATP production was 1.91 and 1.89 times that of the other two composition groups (P < 0.05), and 1.88 and 1.85 times that of curcumin and lactoferrin used alone (P < 0.05). It can be seen that curcumin and lactoferrin have a synergistic effect in improving muscle cell energy production and enhancing muscle vitality.

[0045] The embodiments described above are only a part of the embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative efforts shall fall within the scope of protection of the present invention.

Claims

1. A composition capable of alleviating muscle atrophy, characterized in that, The composition comprises curcumin and milk-derived protein, and the mass ratio of curcumin to milk-derived protein is 1-3:1-3.

2. The composition according to claim 1, wherein The milk-derived protein is one or more of lactoferrin, α-lactalbumin or β-lactoglobulin.

3. The composition according to claim 1 or 2, characterized in that, The mass ratio of curcumin to milk-derived protein is 1-2:1-2.

4. A product, characterized in that, The product comprises the composition according to any one of claims 1-3.

5. The product according to claim 4, characterized in that, The product is a feed, a health food or a medicine, and the product further comprises excipients acceptable in feeds, health foods or medicines.

6. Use of the composition according to any one of claims 1 to 3 or the product according to claim 4 in the preparation of a product capable of delaying muscle aging, characterized in that, The product is a feed, a health food or a medicine.

7. The application according to claim 6, wherein The delaying of muscle aging includes at least one of the following: (1) alleviating muscle atrophy; (2) promoting muscle generation; (3) enhancing muscle motor ability.

8. The application according to claim 7, wherein The enhancing of muscle motor ability includes enhancing muscle strength or enhancing muscle endurance.

9. Use of the composition according to any one of claims 1 to 3 or the product according to claim 4 in the preparation of a product capable of alleviating weight loss caused by poor muscle condition, characterized in that, The product is a feed, a health food or a medicine.

10. Use of the composition according to any one of claims 1-3 or the product according to claim 4 in the preparation of a product capable of maintaining blood glucose stability, characterized in that, The product is a feed, a health food or a medicine.

Images